BiomX is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets.
The Company’s platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology. Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset Global Investments, and SBI.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2015
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was BiomX Inc founded?
BiomX Inc was founded in 2015.
What industry is BiomX Inc in?
BiomX Inc operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is BiomX Inc based?
BiomX Inc is headquartered in Ness Ziona, Israel.
Find investors for your startup like BiomX Inc
Gritt sends AI-personalised outreach to each investor — from your Gmail